3 Adhesives Leader, Oleochemical Additives Maker and Pharma Excipients Producer Stocks With a Strong Future Roadmap: Pidilite Industries, Fine Organic Industries and Sudeep Pharma

Adhesive, additive and pharma ingredient stocks bring together companies with a visible plan for the years ahead. Pidilite Industries, Fine Organic Industries and Sudeep Pharma cover an adhesives leader, an oleochemical additives maker and a pharma excipients producer.

This list covers three adhesive, additive and pharma ingredient stocks with complete current figures: Pidilite Industries, Fine Organic Industries and Sudeep Pharma. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Adhesive, Additive and Pharma Ingredient Stocks?

Adhesive, additive and pharma ingredient stocks are listed chemical companies that make adhesives and construction chemicals, additives for food, plastics and cosmetics, and excipients and nutritional ingredients for medicines and food. Their earnings depend on volumes, raw material prices and export demand.

Adhesive, Additive and Pharma Ingredient Stocks at a Glance

On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing adhesive, additive and pharma ingredient stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in adhesive, additive and pharma ingredient stocks can use the coming numbers to test whether growth is holding.

Why Do Adhesive, Additive and Pharma Ingredient Stocks Have a Strong Roadmap in India?

Adhesive, additive and pharma ingredient stocks have a strong roadmap in India because housing and construction activity, wider use of specialised additives and global demand for pharma and food ingredients keep widening the market for Indian speciality chemical firms.

• Home improvement. Adhesives and sealants follow construction work.
• Specialised additives. Food and plastics makers need tailored inputs.
• Pharma ingredients. Excipients support medicine and nutrition makers.

Why Pidilite Industries Features Among These Adhesive, Additive and Pharma Ingredient Stocks

Among the adhesive, additive and pharma ingredient stocks on this list, Pidilite Industries is India's leading adhesives and construction chemicals company and the maker of Fevicol, Dr. Fixit, M-Seal and Fevikwik, among other brands.

Revenue rose from Rs 9,957 crore in FY22 to Rs 14,867 crore in FY26, a compound annual growth rate of 10.5%. Net profit grew from Rs 1,207 crore in FY22 to Rs 2,471 crore in FY26, which works out to a compound annual growth rate of 19.6%.

In the June 2026 quarter, revenue grew 21.0% year on year to Rs 4,644 crore, while net profit rose 30.3% to Rs 884 crore. The company has a return on equity of 22.6%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 150,953 crore. The stock trades at a P/E of 56.4, above the industry P/E of 35.1.

Roadmap: The company has a strong brand and a vast distribution network, and it continues to add products in waterproofing, paints and construction chemicals. Premium categories and new launches contribute to growth in housing and renovation.

What to watch: Check volume growth in consumer and bazaar products and the trend in raw material prices.

Why Fine Organic Industries Features Among These Adhesive, Additive and Pharma Ingredient Stocks

Among the adhesives, oleochemical additives and excipient shares on this list, Fine Organic Industries is a leading maker of oleochemical-based additives used in food, plastics, cosmetics and coatings, selling to customers in India and overseas.

In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%.

Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1.

Roadmap: The company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.

What to watch: Monitor raw material prices, export demand and the pace of new capacity addition.

Why Sudeep Pharma Features Among These Adhesive, Additive and Pharma Ingredient Stocks

Among the three companies on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.

The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1.

Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore.

Roadmap: Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.

What to watch: Check capacity expansion progress and export revenue growth.

Pidilite Industries vs Fine Organic Industries vs Sudeep Pharma on Key Financials

The table below sets the three adhesive, additive and pharma ingredient stocks side by side on revenue, profit and margin, using reported figures.

Pidilite Industries posts the highest return on equity in this group at 22.6%. Pidilite Industries has the largest FY26 revenue at Rs 14,867 crore, and Sudeep Pharma shows the fastest revenue growth with a 17.6% compound annual rate. A useful habit with adhesive, additive and pharma ingredient stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several speciality chemical and ingredient stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Adhesive, Additive and Pharma Ingredient Stocks

Every theme carries risks that deserve a check before any decision. For these adhesive, additive and pharma ingredient stocks, the main points are: Long-term adhesives, oleochemical additives and excipient shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Input costs. Metal and material prices can move margins.
• Competition. Rivals can influence pricing and market share.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter adhesive, additive and pharma ingredient stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Adhesive, Additive and Pharma Ingredient Stocks

Adhesive, additive and pharma ingredient stocks suit investors who prefer to study business strength before price moves. Pidilite Industries, Fine Organic Industries and Sudeep Pharma each have a clear plan to grow. Based on the 27 October 2026 close, Pidilite Industries trades at Rs 1,450, Fine Organic Industries at Rs 5,107.5 and Sudeep Pharma at Rs 1,022.4. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these adhesive, additive and pharma ingredient stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track adhesive, additive and pharma ingredient stocks, set price alerts and get research-backed stock ideas.

What are adhesive, additive and pharma ingredient stocks?

Ans. Adhesive, additive and pharma ingredient stocks are listed chemical companies that make adhesives and construction chemicals, additives for food, plastics and cosmetics, and excipients and nutritional ingredients for medicines and food. Their earnings depend on volumes, raw material prices and export demand. This list looks at three of them, Pidilite Industries, Fine Organic Industries and Sudeep Pharma, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.

Which adhesive, additive and pharma ingredient stocks are covered in this list?

Ans. This list covers Pidilite Industries, Fine Organic Industries and Sudeep Pharma. Based on the 27 October 2026 close, Pidilite Industries traded at Rs 1,450, Fine Organic Industries at Rs 5,107.5 and Sudeep Pharma at Rs 1,022.4. Their return on equity ranges from 15.7% to 22.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 17.6%.

Why do adhesive, additive and pharma ingredient stocks have a strong future roadmap in India?

Ans. Adhesive, additive and pharma ingredient stocks have a strong roadmap in India because housing and construction activity, wider use of specialised additives and global demand for pharma and food ingredients keep widening the market for Indian speciality chemical firms. The main drivers are as follows. Home improvement. Adhesives and sealants follow construction work. Specialised additives. Food and plastics makers need tailored inputs. Pharma ingredients. Excipients support medicine and nutrition makers. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Pidilite Industries performed financially?

Ans. Revenue rose from Rs 9,957 crore in FY22 to Rs 14,867 crore in FY26, a compound annual growth rate of 10.5%. Net profit grew from Rs 1,207 crore in FY22 to Rs 2,471 crore in FY26, which works out to a compound annual growth rate of 19.6%. In the June 2026 quarter, revenue grew 21.0% year on year to Rs 4,644 crore, while net profit rose 30.3% to Rs 884 crore. The company has a return on equity of 22.6%, a debt to equity ratio of 0.04 and a market capitalisation of Rs 150,953 crore. The stock trades at a P/E of 56.4, above the industry P/E of 35.1. Looking ahead, the company has a strong brand and a vast distribution network, and it continues to add products in waterproofing, paints and construction chemicals. Premium categories and new launches contribute to growth in housing and renovation.

How has Fine Organic Industries performed financially?

Ans. Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1. Looking ahead, the company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.

How has Sudeep Pharma performed financially?

Ans. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.

What risks should investors check before buying adhesive, additive and pharma ingredient stocks?

Ans. Investors should check a few risks before buying adhesive, additive and pharma ingredient stocks. Input costs. Metal and material prices can move margins. Competition. Rivals can influence pricing and market share. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of adhesive, additive and pharma ingredient stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.